DaVita (DVA) vs Sotera Health (SHC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
DaVita (DVA) has outperformed Sotera Health (SHC) over the past year, gaining 34.9% versus a gain of 11.3%. Over five years, DVA leads with a +57.5% price change compared with -31.5% for SHC. DaVita is the larger company by market cap ($11.28 billion vs $5.11 billion), about 2.2 times the size.
On valuation, DaVita trades at a lower forward P/E (10.3x vs 16.7x for Sotera Health). Sotera Health converts more of its revenue into profit, with a net margin of 6.7% versus 5.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DVA | SHC |
|---|---|---|
| Share price | $176.78 | $17.90 |
| Market cap | $11.28B | $5.11B |
| 1-day change | -2.01% | -1.92% |
| YTD return | +55.60% | +1.47% |
| 1-year return | +34.91% | +11.32% |
| 5-year return | +57.54% | -31.55% |
| P/E ratio (TTM) | 14.93 | 31.40 |
| Forward P/E | 10.31 | 16.65 |
| EPS (TTM) | $11.84 | $0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.64B | $1.16B |
| Revenue growth (YoY) | +6.46% | +5.74% |
| Net income (latest FY) | $746.80M | $77.95M |
| Gross margin | — | 55.48% |
| Operating margin | 14.98% | — |
| Net margin | 5.47% | 6.70% |
| 52-week high | $247.49 | $19.85 |
| 52-week low | $101.00 | $13.09 |
| Distance from 52-week high | -28.57% | -9.82% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +24.37% | +26.93% |
| Average volume | 776.03K | 2.53M |
| Shares outstanding | 63.80M | 285.37M |
| Employees | 78,000 | 3,000 |
| Sector | Health Care | Health Care |
| Industry | Misc Health and Biotechnology Services | Misc Health and Biotechnology Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DaVita is about 2.2 times larger than Sotera Health by market value ($11.28B vs $5.11B).
- DVA has outperformed SHC by 23.6 percentage points over the past year.
- Sotera Health trades at a higher earnings multiple (31.4x vs 14.9x trailing P/E).
About DaVita
DVA stock →DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States.
Health Care · Misc Health and Biotechnology Services · 78,000 employees
About Sotera Health
SHC stock →Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs.
Health Care · Misc Health and Biotechnology Services · 3,000 employees
DVA vs SHC FAQ
Which is bigger, DaVita or Sotera Health?
DaVita (DVA) is larger, with a market capitalization of $11.28B compared with $5.11B for Sotera Health (SHC).
Which stock has performed better over the past year, DVA or SHC?
DVA returned +34.91% over the past 12 months, compared with +11.32% for SHC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DVA or SHC?
DVA has the lower trailing P/E at 14.9, versus 31.4 for SHC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are DaVita and Sotera Health in the same industry?
Yes. Both are classified in the Misc Health and Biotechnology Services industry within the Health Care sector.